References
Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y et al (2002) Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13:928–943 doi:10.1093/annonc/mdf155
Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894–895
Sharma VR, Fleming DR, Slone S (2000) Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96:1184–1186
Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post transplantation lymphoproliferative disorder. N Engl J Med 345:1000 doi:10.1056/NEJM200109273451315
Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE et al (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486–1488 doi:10.1182/blood.V99.4.1486
Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lobuglio AF, Jonas C, Kippenstein D, Dallire B, Varns C (1999) Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276
Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W et al (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 102:1930 doi:10.1182/blood-2003-05-1403
Ng HJ, Lim LC (2001) Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 80:549–552 doi:10.1007/s002770100346
Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69 doi:10.1056/NEJM200101043440120
Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Hiroe K, Obara S et al (2004) Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol 83:58–60 doi:10.1007/s00277-003-0748-4
Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M et al (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4:599–608 doi:10.1517/14740338.4.3.599
Pereau G, Dris N, Estines O, Derancourt C, Levy S, Bernard P (2006) Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 155:1053–1056 doi:10.1111/j.1365-2133.2006.07451.x
Yang SH, Kuo SH (2008) Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 87:325–327 doi:10.1007/s00277-007-0396-1
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsutsumi, Y., Shigematsu, A., Hashino, S. et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido. Ann Hematol 88, 375–377 (2009). https://doi.org/10.1007/s00277-008-0585-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0585-6